Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Gynecology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    May 2020
  1. MATSUO K, Matsuzaki S, Nusbaum DJ, Machida H, et al
    Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.
    Eur J Cancer. 2020;133:33-46.
    PubMed     Abstract available


  2. WENZEL HHB, Smolders RGV, Beltman JJ, Lambrechts S, et al
    Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review.
    Eur J Cancer. 2020;133:14-21.
    PubMed     Abstract available


    April 2020
  3. LOK C, van Trommel N, Massuger L, Golfier F, et al
    Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease.
    Eur J Cancer. 2020;130:228-240.
    PubMed     Abstract available


    March 2020
  4. BERNEY DM, Shamash J, Stoneham S, Lockley M, et al
    Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 18. pii: S0959-8049(20)30048.
    PubMed    


  5. ONDA T, Satoh T, Ogawa G, Saito T, et al
    Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Eur J Cancer. 2020;130:114-125.
    PubMed     Abstract available


  6. PASHANKAR F, Frazier AL
    Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 13. pii: S0959-8049(20)30047.
    PubMed    


    February 2020
  7. JENSEN PT, Schnack TH, Froding LP, Bjorn SF, et al
    Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer - A population-based study.
    Eur J Cancer. 2020;128:47-56.
    PubMed     Abstract available


    January 2020
  8. JANSEN EEL, Zielonke N, Gini A, Anttila A, et al
    Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.
    Eur J Cancer. 2020 Jan 21. pii: S0959-8049(19)30868.
    PubMed     Abstract available


  9. BAGRATUNI T, Mavrianou N, Gavalas NG, Tzannis K, et al
    JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Eur J Cancer. 2020;126:125-135.
    PubMed     Abstract available


  10. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020;126:104-105.
    PubMed    


  11. WOJTYLA C, Janik-Koncewicz K, La Vecchia C
    Cervical cancer mortality in young adult European women.
    Eur J Cancer. 2020;126:56-64.
    PubMed     Abstract available


    December 2019
  12. RUSAN M, Andersen RF, Jakobsen A, Steffensen KD, et al
    Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    Eur J Cancer. 2019;125:121-129.
    PubMed     Abstract available


    November 2019
  13. FLAUM N, Crosbie EJ, Woodward ER, Lalloo F, et al
    Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.
    Eur J Cancer. 2019;124:88-90.
    PubMed    


  14. LOOPIK DL, IntHout J, Melchers WJG, Massuger LFAG, et al
    Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study.
    Eur J Cancer. 2019;124:102-109.
    PubMed     Abstract available


    September 2019
  15. CHOI MC, Oh J, Lee C
    Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;121:94-97.
    PubMed    


    July 2019
  16. VAN DER HEL OL, Timmermans M, van Altena AM, Kruitwagen RFPM, et al
    Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
    Eur J Cancer. 2019;118:97-104.
    PubMed     Abstract available


  17. LEE CK, Asher R, Friedlander M, Gebski V, et al
    Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    Eur J Cancer. 2019;117:99-106.
    PubMed     Abstract available


    June 2019
  18. ALFONZO E, Wallin E, Ekdahl L, Staf C, et al
    No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study.
    Eur J Cancer. 2019;116:169-177.
    PubMed     Abstract available


  19. PERSSON J, Salehi S, Bollino M, Lonnerfors C, et al
    Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.
    Eur J Cancer. 2019;116:77-85.
    PubMed     Abstract available


  20. ROUSSET-JABLONSKI C, Selle F, Adda-Herzog E, Planchamp F, et al
    Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.
    Eur J Cancer. 2019;116:35-44.
    PubMed     Abstract available


  21. PERRONE F, De Laurentiis M, De Placido S, Orditura M, et al
    Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297.
    PubMed     Abstract available


    May 2019
  22. FROEHLICH K, Schmidt A, Heger JI, Al-Kawlani B, et al
    Breast cancer, placenta and pregnancy.
    Eur J Cancer. 2019;115:68-78.
    PubMed     Abstract available


    April 2019
  23. NEWTON C, Murali K, Ahmad A, Hockings H, et al
    A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2019;113:19-27.
    PubMed     Abstract available


    February 2019
  24. DELLE MARCHETTE M, Ceppi L, Andreano A, Bonazzi CM, et al
    Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.
    Eur J Cancer. 2019;111:61-68.
    PubMed     Abstract available


  25. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed     Abstract available


  26. FRIJSTEIN MM, Lok CAR, Short D, Singh K, et al
    The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;109:162-171.
    PubMed     Abstract available


    January 2019
  27. JORGENSEN SL, Mogensen O, Wu CS, Korsholm M, et al
    Survival after a nationwide introduction of robotic surgery in women with early-stage endometrial cancer: a population-based prospective cohort study.
    Eur J Cancer. 2019;109:1-11.
    PubMed     Abstract available


    November 2018
  28. MENZER C, Beedgen B, Rom J, Duffert CM, et al
    Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
    Eur J Cancer. 2018;104:239-242.
    PubMed    


    September 2018
  29. CAMPONE M, Im SA, Iwata H, Clemons M, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Eur J Cancer. 2018;103:147-154.
    PubMed     Abstract available


    July 2018
  30. BOUVARD B, Chatelais J, Soulie P, Hoppe E, et al
    Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Eur J Cancer. 2018;101:87-94.
    PubMed     Abstract available


  31. BRETTHAUER M, Goderstad JM, Loberg M, Emilsson L, et al
    Uterine morcellation and survival in uterine sarcomas.
    Eur J Cancer. 2018;101:62-68.
    PubMed     Abstract available


  32. HESCOT S, Haissaguerre M, Pautier P, Kuhn E, et al
    Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.
    Eur J Cancer. 2018;97:57-58.
    PubMed    


    June 2018
  33. MEYS EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, et al
    Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer.
    Eur J Cancer. 2018;100:55-64.
    PubMed     Abstract available


    May 2018
  34. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    PubMed     Abstract available


  35. MANDALA M, Merelli B, Indriolo A, Tondini C, et al
    Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
    Eur J Cancer. 2018;95:130-132.
    PubMed    


    April 2018
  36. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Abstract available


  37. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Abstract available


  38. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Abstract available


  39. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    PubMed    


    January 2018
  40. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    PubMed     Abstract available


  41. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Abstract available


    November 2017
  42. TIMMERMANS M, Sonke GS, Van de Vijver KK, van der Aa MA, et al
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
    Eur J Cancer. 2017;88:31-37.
    PubMed     Abstract available


  43. TEMKIN SM, Miller EA, Samimi G, Berg CD, et al
    Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Eur J Cancer. 2017;87:182-188.
    PubMed     Abstract available


  44. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Abstract available


    October 2017
  45. VERSLUIS MAC, Marchal S, Plat A, de Bock GH, et al
    The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Eur J Cancer. 2017;86:285-295.
    PubMed     Abstract available


  46. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Abstract available


    September 2017
  47. VANDERSTICHELE A, Busschaert P, Olbrecht S, Lambrechts D, et al
    Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2017;86:5-14.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: